KemPharm, Inc. to Report Q1 2015 Results

CORALVILLE, Iowa, May 18, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity ("NME") prodrugs, announced today that the Company will host a conference call and live audio webcast on Wednesday, May 27, 2015, at 4:30 p.m. ET, to discuss its corporate and financial results for the quarter ended March 31, 2015.

Conference Call Information:

Interested participants and investors may access the conference call by dialing either:

  • (866) 395-2480 (U.S.)
  • (678) 509-7538 (international)

An audio webcast will be accessible via the Investor Relations section of the KemPharm website

A replay of the call will be available for 90 days beginning at approximately 5:30 p.m., ET on May 27, 2015.

About KemPharm

KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of NME prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.

CONTACT: For KemPharm, Inc.: Gordon K. "Rusty" Johnson 319-665-2575 Media / Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664